Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook
Eli Lilly shares closed Friday near $1,077.75, little changed after a narrow session. The Centers for Medicare & Medicaid Services this week announced a plan to expand GLP‑1 drug access, capping monthly costs at $50 for Medicare beneficiaries. A Trump-era pricing deal also sets lower reference prices for weight-loss drugs. Investors are watching policy shifts as key drivers for LLY’s valuation.